VALLEY COTTAGE, N.Y., Oct. 2 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) today announced that its
Extraordinary General Meetings ('EGMs') were postponed until October 10, 2008
in accordance with its articles of association due to the absence of a quorum.
The postponed EGMs will take place at the offices of Kantor & Co. Law Offices,
14 Abba Hillel Silver Road, Oz House, 12th Floor, Ramat Gan, Israel at 3:00
p.m. Israel time, and 5:30 p.m. Israel time, respectively, on October 10,
2008.
Any proxy votes received at any time up to 48 hours prior to the postponed
EGMs will be included in the total votes counted for the EGMs. Those
shareholders who have a valid 'proof of ownership' in Israel or a letter of
representation from Computershare, the Company's United Kingdom registrars,
and attend the meeting in person will also be permitted to vote.
ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ('XTL') is engaged in the development of
therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is
developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for
the treatment of diabetic neuropathic pain, which is currently in a Phase 2b
study. XTL has out-licensed its novel pre-clinical HCV small molecule
inhibitor program. XTL also has an active in-licensing and acquisition program
designed to identify and acquire additional drug candidates. XTL is publicly
traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; TASE: XTL).
SOURCE XTL Biopharmaceuticals Ltd.
